Novel amphiphilic lipid augments the co-delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment

Boakye, Cedar H. A.; Patel, Ketan; Doddapaneni, Ravi; Bagde, Arvind; Marepally, Srujan; Singh, Mandip

doi:10.1016/j.jconrel.2016.05.017

Cited by 63 publications

(30 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The epidermal thickness of the IMQ group was 4.7-fold higher than that of the control (no treatment) group. Epidermal hyperplasia and stratum corneum thickening (acanthosis and hyperkeratosis, respectively) were obvious in the IMQ group [19]. The abnormal differentiation of the epidermis and infiltration of leukocytes were also observed in the IMQ group as previously reported [16].…”

Section: Resultssupporting

confidence: 61%

Therapeutic Efficacies of Artemisia capillaris Extract Cream Formulation in Imiquimod-Induced Psoriasis Models

Lee

Nam

Kim

et al. 2018

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

A cream formulation containing Artemisia capillaris (AC) extract (ACE) was developed for psoriasis therapy. Although ACE can be dissolved in organic solvents, its topical application is restricted because of toxicities. Therefore, a cream formulation was developed for the convenient and safe local application of ACE on skin lesions. The antipsoriatic properties of the ACE cream were evaluated using an imiquimod- (IMQ-) induced psoriasis-like mouse model. In psoriasis-like mouse models, the cumulative score (redness, thickness, and scaling) of the IMQ + ACE cream group was significantly lower than those of the other groups on day 4 (p < 0.05). The results of the hematoxylin and eosin staining of skin tissues revealed that the epidermal thickness value of the IMQ + ACE cream group was significantly lower than those of the other experimental groups (p < 0.05). The expression level of intracellular adhesion molecule-1 (ICAM-1), which indicates the leukocyte infiltration into the skin and subsequent interactions with keratinocytes, was also lower in the IMQ + ACE cream group than in the IMQ group. These results indicate that ACE cream formulation could be used safely and conveniently for psoriasis treatment.

show abstract

Section: Resultssupporting

confidence: 61%

Therapeutic Efficacies of Artemisia capillaris Extract Cream Formulation in Imiquimod-Induced Psoriasis Models

Lee

Nam

Kim

et al. 2018

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…The epidermal thickness values of control, IMQ, IMQ + TAC, IMQ + ACE10, IMQ + ACE25, and IMQ + ACE50 were 29 ± 3, 101 ± 14, 70 ± 12, 83 ± 6, 73 ± 4, and 55 ± 7 μm, respectively. The H&E staining result of IMQ group revealed the epidermal thickening (acanthosis), rete ridge, and stratum corneum thickening (hyperkeratosis) (Boakye et al, ). The thickness of IMQ group was 3.6‐fold higher than that of control group ( p < .05).…”

Section: Resultsmentioning

confidence: 99%

“…IHC staining results of Ki‐67 in skin tissues of all experimental groups are shown in Figure . Ki‐67 has been used as a keratinocyte proliferation marker for evaluating the antipsoriatic agents in psoriasis‐induced models (Boakye et al, ). Brown color points indicate the expression of Ki‐67.…”

Section: Resultsmentioning

confidence: 99%

Antiproliferation of keratinocytes and alleviation of psoriasis by the ethanol extract of Artemisia capillaris

Lee

Nam

Hong³

et al. 2018

Phytotherapy Research

View full text Add to dashboard Cite

The therapeutic potentials of the ethanol extract of Artemisia capillaris (ACE) for psoriasis were verified in HaCaT cells (as an immortalized human keratinocyte cell line) and imiquimod (IMQ)-induced psoriasis-like mouse models. In HaCaT cells, IC value of ACE was 37.5 μg/ml after incubating for 72 hr. The antiproliferation activity of ACE in HaCaT cells was further verified by apoptosis assays. The percentage of apoptotic population in ACE-treated group was significantly higher than that of control group (p < .05). The result of cell cycle arrest assay also supported the observed antiproliferation efficacy of ACE in HaCaT cells. In IMQ-induced psoriasis-like mouse models, the Psoriasis Area and Severity Index score of ACE (50 mg/ml; ACE50)-treated group was significantly lower than that of IMQ group on Day 4 (p < .05). After topical application of ACE on psoriasis-like lesion for 4 days, the epidermal thickness of (IMQ + ACE50) group was significantly lower than that of IMQ group (p < .05). The expression levels of Ki-67 and intracellular adhesion molecule-1 in excised skin tissues of (IMQ + ACE50) group were also lower than those of IMQ group. All these findings suggest that ACE can be used as a promising antipsoriatic agent.

show abstract

“…[4][5][6][7][8] Up to date, topical therapy remains a preferred treatment strategy for psoriasis because the site of action is direct. The challenge for topical treatment of psoriasis is the poor drug penetration through the psoriatic skin owing to the physiopathology of psoriasis.…”

Section: Introductionmentioning

confidence: 99%

Effects of nanoparticles with hydrotropic nicotinamide on tacrolimus: permeability through psoriatic skin and antipsoriatic and antiproliferative activities

Wan

Pan

Long

et al. 2017

IJN

View full text Add to dashboard Cite

The hybrid system based on nanoparticles (NPs) self-assembled by the conjugations of hyaluronic acid with cholesterol (HA–Chol NPs) combined with nicotinamide (NIC) for tacrolimus (FK506), ie, FK506 NPs–NIC, has been confirmed to exhibit a significant synergistic effect on FK506 permeation through and into intact skin; thus, it may be a promising approach for FK506 to effectively treat skin diseases. The aim of this study was to evaluate its potential for the treatment of psoriasis. In vitro permeation through the psoriatic skin was carried out, and the results revealed that the combination of NPs with NIC exhibited a significant synergistic effect on FK506 deposition within the psoriatic skin (3.40±0.67 μg/cm 2 ) and penetration through the psoriatic skin (30.86±9.66 μg/cm 2 ). The antipsoriatic activity of FK506 NPs–NIC was evaluated through the treatment for imiquimod (IMQ)-induced psoriasis. The psoriasis area and severity index (PASI) score demonstrated that FK506 HA–Chol NPs–NIC exerted the effect on ameliorating the skin lesions comparable to clobetasol propionate (a positive drug for psoriasis) and superior to commercial FK506 ointment (Protopic ® ), and the histological study showed that it presented a synergistic effect on antipsoriasis after FK506 incorporation into NPs combined with NIC hydrotropic system, which might ultimately increase the therapeutic effect and minimize the systemic side effects by reducing the overall dose of FK506. RAW 264.7 cell uptake presented the enhancement of drugs delivered into cells by HA–Chol NPs–NIC. The antiproliferative activity on HaCaT cells identified that FK506 HA–Chol NPs–NIC exhibited significant inhibiting effects on HaCaT proliferation. The results support that the combination of HA–Chol NPs with NIC is a promising approach for FK506 for the treatment of psoriasis.

show abstract

Novel amphiphilic lipid augments the co-delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment

Cited by 63 publications

References 51 publications

Therapeutic Efficacies of Artemisia capillaris Extract Cream Formulation in Imiquimod-Induced Psoriasis Models

Therapeutic Efficacies of Artemisia capillaris Extract Cream Formulation in Imiquimod-Induced Psoriasis Models

Antiproliferation of keratinocytes and alleviation of psoriasis by the ethanol extract of Artemisia capillaris

Effects of nanoparticles with hydrotropic nicotinamide on tacrolimus: permeability through psoriatic skin and antipsoriatic and antiproliferative activities

Contact Info

Product

Resources

About